From: CPNIContractorUpdate Sent: 16 June 2020 17:29 Subject: CPNI Contractor Update (Participating Pharmacies) RE: Community Pharmacy Flu Vaccination Pilot Survey Importance: High
Dear Colleague,
The email below was recently
issued by HSCB to all community pharmacies who participated in the flu
vaccination pilot service last year. I have attached the list of
pharmacies who participated. The closing date for completion of the survey
is 30th June 2020 and can we encourage all pilotpharmacies
to complete the survey. This will be particularly important as we seek to
potentially develop flu vaccination services in community pharmacy this year.
Your support is greatly
appreciated.
Kind regards,
SENT
FOR AND BEHALF OF GERARD GREENE | Chief Executive
Download
Dear Contractor
Supply of Controlled Drugs via the Community Pharmacy Emergency Supply During a Pandemic
The Department of Health has issued a letter issuing further guidance in respect of controlled drugs and the community pharmacy emergency supply during a pandemic service as authorised under Regulation 226 of the Human Medicines Regulations (HMRs) (see attached).
Summary
The letter reminds contractors that controlled drugs in Schedules 2, 3, and 4 Part 1 cannot currently be supplied using the powers conferred by Regulation 226 as advised in the service specification and in correspondence issued by the Medicines Regulatory Group on 1 May 2020.
The letter also contains a table detailing
some commonly prescribed controlled drugs and their legal schedule.
Contractors are reminded that
emergency supplies of Schedule 4 and Schedule 5 controlled drugs are permitted
under Regulations 224 (Emergency sale etc by pharmacist: prescriber unable to
provide prescription) and 225 (Emergency sale etc by pharmacist: at patient’s
request) of the HMRs provided that the conditions outlined in those Regulations
are observed.
Action
Contractors should:
Familiarise their dispensing teams with the advice
CPNI colleagues will continue to support
contractors on these matters.
Kind regards
Mike
Sent on behalf of Prof Mike Mawhinney | Head of Regulatory Affairs
Download
Dear Colleague,
Further concessionary prices have been granted for June 2020:
Drug
Pack Size
Concessionary Price
Alendronic acid 10mg tablets
28
£4.95
Amiloride 5mg tablets
28
£27.00
Amiodarone 200mg tablets
28
£2.85
Azathioprine 25mg tablets
28
£4.09
Azathioprine 50mg tablets
56
£4.96
Clonidine 25microgram tablets
112
£16.99
Co-careldopa 25mg/100mg tablets
100
£15.25
Donepezil 10mg tablets
28
£3.34
Duloxetine 20mg gastro-resistant capsules
28
£8.71
Erythromycin 250mg gastro-resistant tablets
28
£7.37
Ezetimibe 10mg tablets
28
£2.42
Hydroxyzine 10mg tablets
84
£1.84
Ibuprofen 400mg tablets
24
£1.31
Ibuprofen 400mg tablets
84
£4.60
Irbesartan 150mg tablets
28
£8.10
Irbesartan 300mg tablets
28
£6.43
Montelukast 10mg tablets
28
£3.14
Naftidrofuryl 100mg capsules
84
£7.57
Nitrazepam 5mg tablets
28
£4.14
Oxytetracycline 250mg tablets
28
£4.71
Perindopril erbumine 2mg tablets
30
£2.44
Perindopril erbumine 4mg tablets
30
£4.00
Perindopril erbumine 8mg tablets
30
£4.60
Sertraline 100mg tablets
28
£11.99
Sertraline 50mg tablets
28
£6.96
Tolterodine 2mg tablets
56
£21.09
Tranexamic acid 500mg tablets
60
£7.99
Venlafaxine 37.5mg tablets
56
£4.51
Venlafaxine 75mg tablets
56
£9.35
Kind regards,
Katherine
SENT
FOR AND BEHALF OF KATHERINE KIDD | Head of Pharmacy Development
Dear Colleague,
Community Pharmacists, General Practice Pharmacists and BSO have
provided some feedback on the Emergency Supply during a Pandemic Service, which
has been in operation since 6th April 2020. A number of
learning themes have emerged for both GP practices and community pharmacists;
these are summarised in the attached HSCB correspondence.
If you are having ongoing issues with individual GP practices,
in relation to the service, please contact your local HSCB office to discuss. Similarly,
if you have any further queries about the service or are unsure about when the
ESS can be used please do not hesitate to contact Kerry Grimes kgrimes@communitypharmacyni.co.uk.
Yours sincerely
SENT
FOR AND BEHALF OF GERARD GREENE | Chief Executive
Download
Sent to Participating Pharmacies Only
Dear Colleague,
The email below was recently
issued by HSCB to all community pharmacies who participated in the flu
vaccination pilot service last year. I have attached the list of
pharmacies who participated. The closing date for completion of the survey
is 30th June 2020 and can we encourage all pilotpharmacies
to complete the survey. This will be particularly important as we seek to
potentially develop flu vaccination services in community pharmacy this year.
Your support is greatly
appreciated.
Kind regards,
SENT FOR AND BEHALF OF GERARD GREENE | Chief Executive
HSCB email to
participating pharmacies
on 9th June 2020 ……….
We would like to thank you for taking part in
the Community Pharmacy Flu Vaccine (CPFV) pilot service which enabled a large
number of frontline Healthcare workers to receive the seasonal flu vaccine
from community pharmacies across the Western LCG area. The CPFV pilot service
ended on 31st March 2020.As part of
the CPFV pilot service, the Medicines Optimisation Information Centre (MOIC)
are evaluating the service. This requires the pharmacies that participated in
the pilot, to complete a pharmacist evaluation survey. The survey can be
accessed at https://consultations.nidirect.gov.uk/hsc-northern-health-social-care-trust/75970933and is available for completion now. It will
only take 10 minutes to complete and will have a closing date of 30TH
June 2020. Your feedback is important to us and
is vital for HSCB to inform commissioning decisions for future service
development. We would therefore encourage you to complete the survey.
Download
Dear Contractor
Epidyolex: Advanced Notice of a Forthcoming Amendment to the Misuse of Drugs Regulations (NI) 2002
The Department of Health has issued
advanced notice of an amendment to the Misuse of Drugs Regulations (NI) 2020
which is expected to come into force on 24 June 2020 (see attached).
Summary
The letter indicates that:
Epidyolex, a cannabis-based medicine,
will be rescheduled from S2 to the Regulations to S5 under a specified
definition.
The recommended definition for
Epidyolex within S5 to the Regulations is as follows:
A liquid formulation—
(a) containing cannabidiol obtained by extraction and purification from cannabis;
(b) where the concentration of –
delta-9-tetrahydrocannabinol is not more than 0.1 milligram per millilitre; and
cannabidiol is 95-105 milligrams per millilitre;
(c) which is presented in a bottle, as an oral solution for oral administration; and
(d) which was approved for marketing by the European Commission on 19th September 2019.
Contractors
are reminded that Epidyolex is licensed for treatment of specific conditions
(see letter for details), and that the rescheduling of Epidyolex from S2 to S5
means that it will become exempt from most of the requirements for controlled
drugs such as register, prescription and safe custody requirements.
Action
Contractors should:
Familiarise their dispensing teams with the proposed amendments
CPNI colleagues will continue to support
contractors and their staff as these changes roll out
Kind regards
Mike
Sent on behalf of Prof Mike Mawhinney | Head of Regulatory Affairs
Download
WhatsApp Business Terms of Service can be found here and privacy policy hereUCA-NI Privacy Policy We take your privacy seriously and do not share or sell any personal details with third parties for commercial purposes. If you have any questions, please contact the CPNI office. You can withdraw your consent to be contacted at any time by calling 028 9069 0444 or by emailing info@communitypharmacyni.co.uk. CPNI Data Protection Policy and Data Retention policy can be found Click Here
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
